Literature DB >> 11841436

Spontaneous clinical regression in chronic lymphocytic leukaemia.

Ranjit Thomas1, Isabel Ribeiro, Patricia Shepherd, Peter Johnson, Margaret Cook, Anil Lakhani, Richard Kaczmarski, Patrick Carrington, Daniel Catovsky.   

Abstract

Chronic lymphocytic leukaemia (CLL) is a B-cell disorder, which has a median survival of over 10 years from diagnosis for stage A disease. The natural history of stage A disease is generally indolent or only slowly progressive. It is less well known that CLL may undergo spontaneous regression. We report a series of 10 such cases (eight stage A and two stage B) followed at our institutions.

Entities:  

Mesh:

Year:  2002        PMID: 11841436

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Reactivation of latent Epstein Barr virus infection induces remission of splenic lymphoma with villous lymphocytes.

Authors:  Markus Hansson; Annika Linde; Inge Olsson
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Timothy G Call; Clive S Zent; Jose F Leis; Betsy LaPlant; Deborah A Bowen; Michelle Roos; Kristina Laumann; Asish K Ghosh; Connie Lesnick; Mao-Jung Lee; Chung S Yang; Diane F Jelinek; Charles Erlichman; Neil E Kay
Journal:  Cancer       Date:  2012-07-03       Impact factor: 6.860

3.  CLL: Common Leukemia; Uncommon Presentations.

Authors:  Deepesh Lad; Pankaj Malhotra; Neelam Varma; Manupdesh Singh Sachdeva; Ashim Das; Radhika Srinivasan; Amanjit Bal; Alka Khadwal; Gaurav Prakash; Vikas Suri; Savita Kumari; Sanjay Jain; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-24       Impact factor: 0.900

Review 4.  Second neoplasms in patients with chronic lymphocytic leukemia.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2004-06

5.  Spontaneous hematological remission of acute myeloid leukemia.

Authors:  Maciej Kaźmierczak; Andrzej Szczepaniak; Anna Czyż; Joanna Rupa-Matysek; Mieczysław Komarnicki
Journal:  Contemp Oncol (Pozn)       Date:  2014-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.